MedTrace Logo

Targeting Mitochondrial Fusion and Fission to Prevent Atherosclerosis: Getting the Balance Right

NCT03980548 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2019-06-10

No results posted yet for this study

Summary

Our preliminary data suggests that pharmacological inhibition of the mitochondrial fission protein, Drp1, reduced atherosclerotic plaque volume and attenuated macrophage accumulation within the plaque in an ApoE-/- mouse model of wire-induced carotid arterial injury. Furthermore, we hypothesize that modulation of mitochondrial morphology and metabolism with Drp1 inhibition prevents atherosclerosis by reducing monocyte activation and migration. In this research proposal, our overall objective will be to investigate the role of Drp1 in human monocytes and macrophages as novel therapeutic targets for preventing atherosclerosis.

Conditions

  • CAD Patients

Interventions

PROCEDURE

CABG

Patients undergoing coronary artery bypass graft and patient presented with ACS undergoing PCI

Sponsors & Collaborators

  • National Heart Centre Singapore

    lead OTHER

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-10
Primary Completion
2020-03-31
Completion
2020-03-31

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03980548 on ClinicalTrials.gov